315 related articles for article (PubMed ID: 10364332)
1. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
[TBL] [Abstract][Full Text] [Related]
2. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
3. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
Wang J; Bambara RA; Demeter LM; Dykes C
J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
[TBL] [Abstract][Full Text] [Related]
4. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
[TBL] [Abstract][Full Text] [Related]
5. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
[TBL] [Abstract][Full Text] [Related]
6. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
8. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
9. L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
Wang J; Li D; Bambara RA; Yang H; Dykes C
J Gen Virol; 2013 Jul; 94(Pt 7):1597-1607. PubMed ID: 23535575
[TBL] [Abstract][Full Text] [Related]
10. Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
Genin MJ; Biles C; Keiser BJ; Poppe SM; Swaney SM; Tarpley WG; Yagi Y; Romero DL
J Med Chem; 2000 Mar; 43(5):1034-40. PubMed ID: 10715167
[TBL] [Abstract][Full Text] [Related]
11. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Nikolenko GN; Delviks-Frankenberry KA; Pathak VK
J Virol; 2010 May; 84(10):5238-49. PubMed ID: 20219933
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.
Huang W; Gamarnik A; Limoli K; Petropoulos CJ; Whitcomb JM
J Virol; 2003 Jan; 77(2):1512-23. PubMed ID: 12502865
[TBL] [Abstract][Full Text] [Related]
14. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages.
Archer RH; Wisniewski M; Bambara RA; Demeter LM
Biochemistry; 2001 Apr; 40(13):4087-95. PubMed ID: 11300789
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Cao YL; Li SX; Chen H; Guo Y
Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.
Domaoal RA; Bambara RA; Demeter LM
J Acquir Immune Defic Syndr; 2006 Aug; 42(4):405-11. PubMed ID: 16763521
[TBL] [Abstract][Full Text] [Related]
17. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
[TBL] [Abstract][Full Text] [Related]
18. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
Freimuth WW
Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
[TBL] [Abstract][Full Text] [Related]
19. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro.
Tramontano E; Esposito F; Badas R; Di Santo R; Costi R; La Colla P
Antiviral Res; 2005 Feb; 65(2):117-24. PubMed ID: 15708638
[TBL] [Abstract][Full Text] [Related]
20. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
